Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor
prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise …

Gliomas are highly invasive and are the most common type of primary malignant brain
tumor. The routine treatments for glioma include surgical resection, radiotherapy, and …

Simple Summary Nowadays, there is no univocal therapeutical care for children with optic
pathway gliomas (OPG): different chemotherapy regimens are proposed, but no one has …

Glioma is the most common tumor of the central nervous system (CNS), with a 5-year
survival rate of< 35%. Drug therapy, such as chemotherapeutic and immunotherapeutic …

Background and purpose Currently, the antiangiogenic agent bevacizumab (BVZ) is used as
a treatment option for high-grade glioma (HGG) patients. However, BVZ restores disruptions …

Gliomas are primary intracranial tumors with defined molecular markers available for precise
diagnosis. The prognosis of glioma is bleak as there is an overlook of the dynamic crosstalk …

Glioblastoma is the most common primary malignant tumor of the central nervous system,
which has the characteristics of strong invasion, frequent recurrence, and rapid progression …

CNS tumors are a diverse group of neoplasms that emerge from a variety of different CNS
cell types. These tumors may be benign, malignant, or borderline in nature. The majority of …

Hypoxia spontaneously forms in the interior of glioma tissues and regulates the expression
of various genes. However, the status of hypoxia-driven genes in glioma tissues is not …

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor among
adults. Despite advancements in multimodality therapy for GBM, the overall prognosis …